Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997

Babak Sahragardjoonegani1 Department of Economics,University of Calgary,527 Campus Place N.W.,T2N 4Z6,Calgary,AB,T2N 4Z6,Canada.

Reed F. Beall2 Department of Community Health Sciences, Cumming School of Medicine and O’Brien Institute for Public Health,University of Calgary,3280 Hospital Drive NW,Calgary,AB,T2N 4Z6,Canada.;3 Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine,Brigham and Women’s Hospital / Harvard Medical School,1620 Tremont St., Suite 3030,Boston,MA,02120,USA.

Aaron S. Kesselheim3 Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine,Brigham and Women’s Hospital / Harvard Medical School,1620 Tremont St., Suite 3030,Boston,MA,02120,USA.

Aidan Hollis1 Department of Economics,University of Calgary,527 Campus Place N.W.,T2N 4Z6,Calgary,AB,T2N 4Z6,Canada.Correspondence[email protected]

https://orcid.org/0000-0001-5125-2193

Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997

Additional file 1: Figure A-1.

Additional file 2: Appendices.

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997

Additional file 1: Figure A-1.

Additional file 2: Appendices.

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date